[HTML][HTML] Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia
N Takahashi, T Kyo, Y Maeda, T Sugihara, K Usuki… - Blood, 2011 - Elsevier
Abstract 3759 Imatinib treatment dramatically improves survival in chronic myeloid leukemia
(CML) patients, but whether its effects of imatinib can be considered a cure remains …
(CML) patients, but whether its effects of imatinib can be considered a cure remains …
Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA …
Abstract Around 40–50% of patients with chronic myeloid leukemia (CML) who achieve a
stable complete molecular response (CMR; undetectable breakpoint cluster region-Abelson …
stable complete molecular response (CMR; undetectable breakpoint cluster region-Abelson …
[HTML][HTML] Influence of late treatment on how chronic myeloid leukemia responds to imatinib
ACC Scerni, LA Alvares, AC Beltrão, IR Bentes… - Clinics, 2009 - SciELO Brasil
INTRODUCTION: In Brazil, patients with chronic myeloid leukemia (CML) in the chronic
phase were not given first-line imatinib treatment until 2008. Therefore, there was a long …
phase were not given first-line imatinib treatment until 2008. Therefore, there was a long …
BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase
It is unclear if patients with CML treated with imatinib who fail to achieve BCR/ABL transcript
levels< 10% IS at 3 months ie an early molecular response (EMR) have a better prognosis if …
levels< 10% IS at 3 months ie an early molecular response (EMR) have a better prognosis if …
Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory
S Bouchet, K Titier, N Moore, R Lassalle… - Fundamental & …, 2013 - Wiley Online Library
This study set out to examine in a large real‐life cohort of patients with chronic myeloid
leukemia (CML) the impact of imatinib threshold of 1000 ng/mL on molecular response, as …
leukemia (CML) the impact of imatinib threshold of 1000 ng/mL on molecular response, as …
Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia
A Burchert, S Saussele, E Eigendorff, MC Müller… - Leukemia, 2015 - nature.com
A minority of chronic myeloid leukemia (CML) patients is capable of successfully
discontinuing imatinib. Treatment modalities to increase this proportion are currently …
discontinuing imatinib. Treatment modalities to increase this proportion are currently …
Molecular monitoring of chronic myeloid leukemia
T Hughes, S Branford - Seminars in hematology, 2003 - Elsevier
The tyrosine kinase inhibitor imatinib mesylate (Gleevec)(formerly STI571) has proven to be
an effective and safe new therapy for patients with chronic myeloid leukemia (CML). It has …
an effective and safe new therapy for patients with chronic myeloid leukemia (CML). It has …
Hematopathologic and cytogenetic findings in imatinib mesylate–treated chronic myelogenous leukemia patients: 14 months' experience
RM Braziel, TM Launder, BJ Druker… - Blood, The Journal …, 2002 - ashpublications.org
Imatinib mesylate, an Abl kinase inhibitor, produces sustained complete hematologic
responses (CHRs) in chronic myelogenous leukemia (CML) patients, but the sequence and …
responses (CHRs) in chronic myelogenous leukemia (CML) patients, but the sequence and …
[HTML][HTML] Imatinib and beyond—the new CML study IV: A randomized controlled comparison of imatinib vs imatinib/interferon-alpha vs imatinib/low-dose AraC vs …
U Berger, G Engelich, A Reiter, A Hochhaus… - Annals of …, 2004 - Springer
Management decisions for patients with chronic myeloid leukemia (CML) have become
remarkably complex due to a variety of highly effective treatment options. Therapy for …
remarkably complex due to a variety of highly effective treatment options. Therapy for …
Molecular monitoring of BCR–ABL as a guide to clinical management in chronic myeloid leukaemia
T Hughes, S Branford - Blood reviews, 2006 - Elsevier
Molecular monitoring of BCR–ABL transcript levels by real-time quantitative PCR is
increasingly used to assess treatment response in patients with chronic myeloid leukaemia …
increasingly used to assess treatment response in patients with chronic myeloid leukaemia …